Compare BNBX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNBX | PPCB |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.7M |
| IPO Year | N/A | N/A |
| Metric | BNBX | PPCB |
|---|---|---|
| Price | $1.56 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 280.3K | 270.0K |
| Earning Date | 02-12-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,136,935.00 | N/A |
| Revenue This Year | $253.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.11 | N/A |
| 52 Week Low | $1.16 | $0.24 |
| 52 Week High | $145.73 | $145.46 |
| Indicator | BNBX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 39.43 | 22.64 |
| Support Level | $1.50 | $0.24 |
| Resistance Level | $1.73 | $0.34 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 42.87 | 18.88 |
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.